Comment on Fust et al. The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan.

COVID-19 Japan SARS-CoV-2 coronavirus cost-effectiveness vaccination

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
17 Oct 2024
Historique:
received: 15 05 2024
revised: 04 10 2024
accepted: 11 10 2024
medline: 26 10 2024
pubmed: 26 10 2024
entrez: 26 10 2024
Statut: epublish

Résumé

We noted three key inconsistencies in the Moderna-funded cost-effectiveness analysis by Fust et al [...].

Identifiants

pubmed: 39460340
pii: vaccines12101174
doi: 10.3390/vaccines12101174
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Pfizer (United States)
ID : n/a

Auteurs

Hannah R Volkman (HR)

Pfizer Inc., New York, NY 10001, USA.

Jennifer L Nguyen (JL)

Pfizer Inc., New York, NY 10001, USA.

Mustapha M Mustapha (MM)

Pfizer Inc., New York, NY 10001, USA.

Luis Jodar (L)

Pfizer Inc., New York, NY 10001, USA.

John M McLaughlin (JM)

Pfizer Inc., New York, NY 10001, USA.

Classifications MeSH